# A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

> **NCT01724177** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 26 (actual)

## Conditions studied

- Adult T-Cell Leukemia-Lymphoma

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01724177
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-12
- **Primary completion:** 2014-11-20
- **Final completion:** 2017-03-21
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724177, "A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01724177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*